Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant plus everolimus vs endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer
2023-506821-12-00Phase 3Authorised
- Sponsor
- Genentech
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer (2 arms), sponsored by Genentech. Primary endpoints: Progression-free survival in ESR1-mutant subpopulation and Progression-free survival in ITT population. Planned start Jun 2024; status: authorised.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506821-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506821-12-00.